Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 14/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310186 | 0.92 | KIF11 (0.70) | KIF11MAPTCYP1A2CYP2C9CYP11B1 | |
| SCHEMBL4888035 | 0.82 | KIF11 (0.86) | KIF11GSK3BMAPTCYP1A2CYP2C9 | |
| SCHEMBL4897861 | 0.80 | KIF11 (0.72) | KIF11MAPTCYP1A2CYP2C9CYP11B1 | |
| SCHEMBL4888861 | 0.80 | KIF11 (0.86) | KIF11GSK3BCYP1A2CYP2C9CYP11B1 | |
| SCHEMBL4896533 | 0.78 | KIF11 (0.51) | KIF11GSK3BMAPTCYP1A2CYP2C9 | |
| SCHEMBL4595128 | 0.77 | KIF11 (0.50) | KIF11PTGS2PTGS1CYP11B1CYP11B2 | |
| SCHEMBL4888989 | 0.77 | KIF11 (0.68) | KIF11MAPTCYP1A2CYP2C9CYP11B1 | |
| SCHEMBL4890959 | 0.77 | KIF11 (0.68) | KIF11MAPTCYP1A2CYP2C9CYP11B1 | |
| SCHEMBL9024780 | 0.76 | KIF11 (0.67) | KIF11MAPT | |
| SCHEMBL4897585 | 0.75 | KIF11 (0.58) | KIF11GSK3BMAPTCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | claimed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | claimed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | KIF11 562/4885GSK3B 1444/4885PTGS2 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.